S&P 500
7,755.20
+0.25%
Dow Jones
53,817.00
-0.01%
Nasdaq 100
29,763.50
+0.67%
Russell 2000
3,048.17
+0.64%
FTSE 100
10,856.80
+0.21%
Nikkei 225
68,595.70
+2.10%
ADMA Biologics

ADMA Biologics (ADMA) Q2 2026 Earnings

Reported Aug 5, 2026 at 4:10 PM ET · SEC Source

Q2 26 EPS GAAP

$0.16

MISS 2.02%

Est. $0.16

Q2 26 Revenue

$124.4M

MISS 0.77%

Est. $125.4M

vs S&P Since Q2 26

+10.3%

BEATING MARKET

ADMA +10.8% vs S&P +0.6%

Market Reaction

Did ADMA Beat Earnings? Q2 2026 Results

ADMA Biologics delivered a modest miss on both the top and bottom lines in the second quarter of 2026, as the plasma-derived immunotherapy company reported revenue of $124.39 million, up 2.0% year over year but falling short of the $125.36 million co… Read more ADMA Biologics delivered a modest miss on both the top and bottom lines in the second quarter of 2026, as the plasma-derived immunotherapy company reported revenue of $124.39 million, up 2.0% year over year but falling short of the $125.36 million consensus by 0.77%. GAAP earnings per share came in at $0.16, trailing the $0.16 analyst estimate by 2.02%. The headline numbers masked a more complex story underneath: ASCENIV, the company's higher-margin flagship product, generated $102.92 million in revenue, up 24% from a year ago, while BIVIGAM fell 49% to $19.42 million, creating a product mix that lifted gross margin to 69% from 55% but constrained overall top-line growth. That margin expansion drove gross profit up 28% to $86.28 million, even as rising R&D spending tied to the SG-001 development program and increased legal-related professional fees weighed on the income statement. Results arrive against a backdrop of securities fraud litigation alleging channel stuffing in prior periods, adding an overhang management has not yet resolved. The company reiterated its full-year 2026 guidance, targeting total revenue of $530 million to $560 million and Adjusted EBITDA of $265 million to $300 million.

Key Takeaways

  • • ASCENIV demand acceleration with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024
  • • Gross margin expansion to 69% from 55% YoY driven by favorable product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing process
  • • Increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization for ASCENIV
  • • BIVIGAM demand stabilization with sequential improvement in utilization and revenue from Q1 2026 trough levels

ADMA Forward Guidance & Outlook

ADMA reiterated FY2026 financial guidance: total revenue of $530 million to $560 million, Adjusted Net Income of $170 million to $200 million, and Adjusted EBITDA of $265 million to $300 million. The outlook reflects sustained competitive dynamics and pricing pressure within the U.S. immune globulin market through the balance of the year. ASCENIV is expected to remain the principal growth driver, supported by accelerating demand, expanding physician adoption, and an increasing body of differentiated clinical and real-world evidence. Management expressed confidence in meeting or exceeding guidance ranges for 2026.

24/7 Wall St

ADMA YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

ADMA Revenue by Segment

With YoY comparisons, source: SEC Filings

Q4 25 Q2 26

“Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV's growth trajectory. ASCENIV continued to outperform, supported by increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization. Growth in ASCENIV utilization accelerated in the quarter, with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024. BIVIGAM demand continued to stabilize during the quarter, resulting in sequential improvement in utilization and revenue. Together, these trends reinforce our confidence in sustained growth throughout the balance of 2026.”

— Adam Grossman, Q2 2026 Earnings Press Release

Back to ADMA Stock Page